Joao Amorim

Manager, Business Development & Licensing

2024 - Current

Associate, Business Development & Licensing

2023 - 2024

Postdoctoral Fellow

2020 - 2023

- Investigating the role of epigenetic alterations in a mouse genome responsible for the early onset of age-related phenotypes and related diseases

PhD Candidate

2017 - 2019

- Investigating a novel mechanism by which small molecules activate SIRT1 and how they can be used to treat aging and age-related metabolic diseases

Analyst

2021 - 2022

- Performed scientific and investment diligence on biotech companies across multiple therapeutic areas - Contributed to multiple investment memos highlighting the investment thesis of prospective companies, including technical, regulatory, market, financial and intellectual property analysis - Performed deal sourcing by engaging with companies' management teams through introductory calls and investment conferences

Analyst

2020 - 2021

- Prepared risk analyses and mitigation/diligence plans to evaluate early-stage investment opportunities in mitochondria physiology - Identified and prioritize potential programs for pre-seed and seed-stage through in-depth literature review, KOL engagement, and risk analyses

Lab to Market, MBA classes

2019 - 2019

- Assessed commercial opportunities for a vectored antibody delivery technology developed in the Balazs Lab at The Ragon Institute - Identified and defined the TPP for target disease indications, assessed IP, evaluated go-to-market strategy for different indications, defined the regulatory strategy

MSc Student

2013 - 2014

- Studied the impact of mitochondria dysfunction pre-synaptic nerve terminals in an in vitro model of Alzheimer's disease